Tag Archive for: 225Ac
Phase 1 Resulta for 225Ac-LNC1011, a Novel Alpha Emitter Therapy for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxUPDATE: ATNM-400 a Promising Antibody Radioconjugate Delivering 225 Ac
/0 Comments/in Preclinical Research/by MaxPhase I Clinical Trial of AZD2284, AZD2287, and AZD2275
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxThe Phase 1 ACCEL Trial: Actinium-225-PSMA-62
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxOncoACP3: A Potential Game-Changer in Prostate Cancer Theranostics —Why?
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor personalized medicine Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Nutrition and Inflamation: New Research Unveils Five Universal Patient Clusters in Oncology August 19, 2025
- Nuanced Benefits of Fasting-Mimicking Diets: High Protein vs. Low Protein August 18, 2025
- Newsletter 33/2025 August 17, 2025
- One year (almost) of ProstateWarriors.com and where are we? August 16, 2025